Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 12;33(12):1325–1333. doi: 10.1200/JCO.2014.57.4244

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by American Society of Clinical Oncology

PMC Copyright notice

Fig A2. — Kaplan-Meier estimates of overall survival (OS) at interim analyses according to treatment group. (A) OS for full analysis set (patients receiving ≥ one dose of cyclophosphamide [Cy]); median OS was 6.0 months in group receiving Cy/GVAX followed by CRS-207 and 3.4 months in group receiving Cy/GVAX alone. (B) OS for per-protocol analysis set (patients receiving ≥ three doses [≥ two doses of Cy/GVAX and one dose of CRS-207 in arm A or three doses of Cy/GVAX in arm B]); median OS was 7.3 months in group receiving Cy/GVAX followed by CRS-207 and 4.6 months in group receiving Cy/GVAX alone. Solid circles represent censored survival time for alive patients.